News

There are two types of Halloween people: those who like jump scares and those who don’t. But even if you’re a fan of haunted hayrides and movies like The Conjuring, you probably don’t want to ever

Abbott Laboratories' (NYSE: ABT) October price plunge is a signal to buy, as analyst and institutional trends suggest they, too, will be buying the stock. Analyst trends revealed by MarketBeat

After years of underperformance, the healthcare sector may finally be waking up. The Health Care Select Sector SPDR Fund (NYSEARCA: XLV), which tracks the largest U.S. healthcare companies, has

Pfizer Inc. (NYSE: PFE) made a strong move higher after it became the first drug manufacturer to sign on as part of the TrumpRx platform. PFE stock is up nearly 14% since its closing price of

Pfizer (NYSE: PFE) is no stranger to income investors. The drugmaker, famous for treatments including Lipitor, Viagra, and Zoloft, has now increased its dividend payout for 16 consecutive years

After tanking in early August, the world’s most valuable pharmaceutical stock has roared back with a vengeance. That firm is Eli Lilly and Company (NYSE: LLY), the maker of the wildly popular

With many stocks looking overvalued, many investors may be tempted to sell. However, there are several factors to consider before taking profits:

• Time horizon – when an investor will need the

When investors hear that a company will lower prices on its products, their instinctive reaction is to expect a sequential decline in margins and profits, which is not entirely incorrect. However

In the United States' healthcare sector, a new growth theme is emerging that nearly all companies want to capitalize on. Like artificial intelligence for technology stocks, weight loss drug

The biotech sector has been one of the market's laggards for several years now, and 2025 has been no different, at least on the surface. Year-to-date, the iShares Nasdaq Biotechnology ETF (NASDAQ:

After a punishing year that saw its stock fall significantly from a 52-week high of over $630, UnitedHealth Group (NYSE: UNH) has reversed course with remarkable force.

The healthcare sector